WO2000002539A1 - Topisches pflaster mit nichtsteroidalen antirheumatika mit säuregruppe - Google Patents
Topisches pflaster mit nichtsteroidalen antirheumatika mit säuregruppe Download PDFInfo
- Publication number
- WO2000002539A1 WO2000002539A1 PCT/EP1999/004686 EP9904686W WO0002539A1 WO 2000002539 A1 WO2000002539 A1 WO 2000002539A1 EP 9904686 W EP9904686 W EP 9904686W WO 0002539 A1 WO0002539 A1 WO 0002539A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- topical
- plaster according
- matrix
- active ingredient
- topical plaster
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
Definitions
- Topical patch with non-steroidal anti-inflammatory drugs with acid group
- non-steroidal anti-inflammatory drugs are active ingredients that are to be understood as derivatives of acetic acid and propionic acid.
- acetic acid derivatives are indomethacin, acemetacin, tolmetin, diclofenac and lonazolac;
- propionic acid derivatives (profene) ibuprofen, flurbiprofen, fenoprofen, ketoprofen, naproxen and tiaprofen.
- the free carboxyl group is important for the action of this class of substances in that it leads to an enrichment of the active substances in inflammatory tissues with a reduced pH.
- Such complaints are, for example, inflammatory rheumatic diseases of the joints and spine, swelling and inflammation of the soft tissues near the joints, shoulder stiffness, low back pain, lumbago and sports and accident injuries.
- gels, ointments or self-adhesive patch systems can be used for local administration.
- the self-adhesive plaster systems have the advantage over the ointments and gels that the clothing is not contaminated and the plaster has to be applied only once every 1-2 days if it is designed accordingly.
- patches for topical application at the site of action generally consist of an active substance-containing, self-adhesive so-called matrix layer, an often textile backing layer and a protective layer for the matrix which is to be removed before use.
- Textile materials are also not without problems, since materials such as cotton or polyurethane tend to bind or absorb active ingredients or diffusible auxiliaries. Polyurethanes in particular tend to change their physical properties in an impermissible manner.
- the adhesive Its most important function is to anchor the system securely on the skin for the intended wearing time without causing pain or tearing when removed. It should not have an occlusive effect, since skin tolerance decreases with increasing occlusion. Since it is in intimate contact with the active ingredient, it must be sufficiently inert to it in order to obtain a plaster that is stable for at least two years.
- the composition of the adhesive must be tailored to the respective chemical composition of the active ingredients and auxiliary substances.
- the adhesive must have a suitable solubility for the active ingredients. Since the permeation rate depends essentially on the thermodynamic activity, an active substance concentration should be aimed as close as possible to the saturation solubility. In general, because of the relatively high amount of active ingredient to be dispensed, a solubility of at least 5% (g / g) and, for reasons of saving in active ingredient, not more than 30%, better not more than 15% (g / 9) ⁇ should be aimed for.
- polyacrylic adhesive are produced by the radical polymerization of acrylic or methacrylic acid and its derivatives. Additional possible monomers are vinyl compounds such as Vinyl acetate or maleic acid.
- TTS transdermal therapeutic systems
- the patches must be able to deliver enough active ingredient to reach sufficiently high tissue levels in the tissues under the patches, that is, the site of action.
- topical plasters should essentially meet the following requirements as optimally as possible:
- the present invention had for its object to provide a topical patch with non-steroidal anti-inflammatory drugs with free carboxyl groups, which fulfills the aforementioned requirements.
- GB 2 273 044 e.g. Patches described that also include ketoprofen as an active ingredient.
- the active ingredient in the matrix is combined with substances from the group of fatty acid esters, polyoxyethylene derivatives, glycerides, fatty acid esters of propylene glycol and pyrrolidone derivatives that improve skin permeation.
- the adhesive can also come from the group of polyacrylate adhesives. None is said about the physical properties of the backing layer. Cotton is mentioned as a material for textile backing layers, but it binds a large part of the active substance contained in the matrix and thereby negatively influences the release of the active substance.
- Acidic functional groups in the polymer and the use of a plasticizer or permeation enhancer containing carboxyl groups are not described.
- a topical plaster with the active ingredient ketoprofen is described in DE-OS 195 27 306.
- This plaster is characterized by a multi-layer matrix, the individual layers having different water absorption capacities.
- No. 5,702,720 describes a plaster with flurbiprofen as an active ingredient.
- the matrix of this patch also consists of a polyacrylate adhesive that contains polyvinylpyrrolidone as an additional component.
- Polyvinylpyrrolidone is to be regarded as disadvantageous because this polymer shows a strong interaction with carboxyl groups and phenolic OH groups. While it improves adhesion on the Skin, but at the price of a lower release of active ingredient or a higher required amount of active ingredient in the patch.
- WO 95/31193 describes a plaster with ibuprofen as the active substance.
- the matrix consists of two different polyacrylate polymers and - in addition to the active ingredient - also of diethyl phthalate. Diethyl phthalate is not to be regarded as toxicologically harmless since it can penetrate the skin in considerable quantities.
- An acidic plasticizer combined with acidic functional groups in the matrix and a non-steroidal anti-inflammatory drug with free carboxyl groups are not available.
- the acrylate adhesive is cross-linked with polyvalent metal cations, preferably with aluminum.
- the aluminum ions are added to the adhesive solution as aluminum acetylacetonate.
- the organic part of the compound is removed together with the solvents when the adhesive dries; the carboxyl groups of the adhesive now form the counterions of the aluminum cations.
- the resulting networking can be viewed as reversible.
- both the acidic active ingredient and the acidic softening also in interaction with the aluminum ions and thereby gives the matrix good adhesive behavior without the matrix becoming too soft and thus tending to so-called "cold flow".
- this cold flow represents a stability problem, on the other hand, it is noticeable in the fact that, after the plaster has been removed from the skin, adhesive edges can remain on the skin.
- the fatty acid present blocks those sites in the polymer which can also interact with the acidic active substance and thus influence the release properties of the acidic active substance.
- Another advantage is that the presence of the dissociation of the active ingredient acid in favor of the neutral active ingredient acid suppresses and thereby the skin is favored better by the neutral form of the active ingredient.
- the backing layer of the patch consists of a polyester fabric or knitted fabric which is elastic at least in one direction or of an elastic closed-cell foam.
- the P olyestergewebe or knitted fabric retain their elasticity due to the elasticity of the polyester yarns used. They differ from slightly elastic polyester fleeces. Such fleeces are available, but they have the disadvantage that they are only sufficiently elastic in a very thin form and then no longer adequately cover the self-adhesive matrix and protect them from sticking to the packaging material or the clothes when worn. Zen. Even in very thick designs (approx. 150 g / m 2 ), polyester fabrics or knitted fabrics have sufficient elasticity for use as textile backing layers of plaster systems.
- polyester is that of all materials conceivable for such fabrics or knitted fabrics, it is the most inert towards diffusible ingredients of the matrix. It distinguishes itself above all from materials such as cotton, viscose, polyamides or polyvinyl acetates.
- the active substance content itself is also constant over this time, even when stored at an elevated temperature. Degradation products are not observed. This further demonstrates the excellent stability of such plasters.
- the permeation rate can be increased even further by using a backing layer made of a closed-cell foam based on polyethylene, polypropylene, polyvinyl chloride or a copolymer of ethylene and vinyl acetate.
- the cause is an increase in occlusion, which generally increases permeation rates.
- FIG. 2 shows the higher permeation rate using a comparative permeation study using human epidermis as an example for the active ingredient ketoprofen.
- plasters in the sense of the invention is illustrated by Examples 1-3. This method of preparation can be adopted for all non-steroidal active ingredients with acidic groups, although the appropriate concentration must be found individually for each active ingredient.
- 58 g of oleic acid and 26 g of ketoprofen are added to 500 g of Durotak 387-2251 with a solids content of 48% by weight and the mixture is stirred until all of the ketoprofen has dissolved.
- the solution is then coated on a siliconized film to produce the matrix layer and the solvents are removed by drying at 50 ° C. for 20 minutes.
- the coating thickness is chosen so that the dried matrix film has a coating weight of 80 g / m 2 .
- the solution is then coated on a siliconized film to produce the matrix layer and the solvents are removed by drying at 50 ° C. for 20 minutes.
- the coating thickness is chosen so that the dried matrix film has a coating weight of 80 g / m 2 .
- the dried matrix layer is now laminated with a polyester fabric that is elastic in two directions; The finished plasters are punched out from the resulting laminate.
- the solution is then coated on a siliconized film to produce the matrix layer and the solvents are removed by drying at 50 ° C. for 20 minutes.
- Thieves- Layer thickness is chosen so that the dried matrix film has a coating weight of 150 g / m a .
- the dried matrix layer is now laminated with a polyester fabric that is elastic in two directions; The finished plasters are punched out from the resulting laminate.
- the permeation results shown in FIG. 1 were determined by in-vitro permeation studies on human epidermis using the generally known Franz diffusion cell.
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002336732A CA2336732C (en) | 1998-07-09 | 1999-07-06 | Topical plaster with non-steroidal antirheumatic agents with an acid group |
AT99932827T ATE251900T1 (de) | 1998-07-09 | 1999-07-06 | Topisches pflaster mit nichtsteroidalen antirheumatika mit säuregruppe |
JP2000558799A JP2002520270A (ja) | 1998-07-09 | 1999-07-06 | 酸基を持つ非ステロイド系リューマチ治療薬を有する局所用プラスター |
IL14074499A IL140744A0 (en) | 1998-07-09 | 1999-07-06 | Topical patch with non-steroid antirheumatic agents having an acid group |
PL345535A PL192009B1 (pl) | 1998-07-09 | 1999-07-06 | Plaster do stosowania miejscowego, zawierający niesteroidowy środek przeciwreumatyczny |
DE59907381T DE59907381D1 (de) | 1998-07-09 | 1999-07-06 | Topisches pflaster mit nichtsteroidalen antirheumatika mit säuregruppe |
EP99932827A EP1094796B1 (de) | 1998-07-09 | 1999-07-06 | Topisches pflaster mit nichtsteroidalen antirheumatika mit säuregruppe |
MXPA01000128A MXPA01000128A (es) | 1998-07-09 | 1999-07-06 | Parche topico con antirreumaticos no esteroides con grupo acido. |
NZ509216A NZ509216A (en) | 1998-07-09 | 1999-07-06 | Topical plaster with non-steroidal antirheumatic agents with a free carboxyl group |
US09/743,124 US6676962B1 (en) | 1998-07-09 | 1999-07-06 | Topical plaster with non-steroidal antirheumatic agents with an acid group |
HU0103715A HU227839B1 (en) | 1998-07-09 | 1999-07-06 | Topical plaster with non-steroidal antirheumatic agents with an acid group |
AU49075/99A AU750861B2 (en) | 1998-07-09 | 1999-07-06 | Topical plaster with non-steroidal antirheumatic agents with an acid group |
BRPI9911981-1A BR9911981B1 (pt) | 1998-07-09 | 1999-07-06 | esparadrapo tópico com anti-reumático não esteroidal com grupo ácido. |
IL140744A IL140744A (en) | 1998-07-09 | 2000-01-04 | Topical dressing with antacid antirheumatic substances with an acid group |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19830649A DE19830649C2 (de) | 1998-07-09 | 1998-07-09 | Topisches Pflaster mit nichtsteroidalen Antirheumatika mit Säuregruppe |
DE19830649.0 | 1998-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000002539A1 true WO2000002539A1 (de) | 2000-01-20 |
Family
ID=7873428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1999/004686 WO2000002539A1 (de) | 1998-07-09 | 1999-07-06 | Topisches pflaster mit nichtsteroidalen antirheumatika mit säuregruppe |
Country Status (23)
Country | Link |
---|---|
US (1) | US6676962B1 (de) |
EP (1) | EP1094796B1 (de) |
JP (1) | JP2002520270A (de) |
KR (1) | KR100549847B1 (de) |
CN (1) | CN1222280C (de) |
AR (1) | AR019343A1 (de) |
AT (1) | ATE251900T1 (de) |
AU (1) | AU750861B2 (de) |
BR (1) | BR9911981B1 (de) |
CA (1) | CA2336732C (de) |
CZ (1) | CZ290992B6 (de) |
DE (2) | DE19830649C2 (de) |
ES (1) | ES2212584T3 (de) |
HU (1) | HU227839B1 (de) |
IL (2) | IL140744A0 (de) |
MX (1) | MXPA01000128A (de) |
NZ (1) | NZ509216A (de) |
PL (1) | PL192009B1 (de) |
RU (1) | RU2212232C2 (de) |
TR (1) | TR200100022T2 (de) |
TW (1) | TW577760B (de) |
WO (1) | WO2000002539A1 (de) |
ZA (1) | ZA200100172B (de) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10032537A1 (de) * | 2000-07-05 | 2002-01-31 | Labtec Gmbh | Dermales System, enthaltend 2-(3-Benzophenyl)Propionsäure |
WO2003055536A1 (en) * | 2001-12-21 | 2003-07-10 | Coloplast A/S | A wound care device |
WO2004110511A1 (en) * | 2003-06-19 | 2004-12-23 | Coloplast A/S | A wound care device |
WO2006013337A2 (en) | 2004-08-03 | 2006-02-09 | Tissuemed Limited | Tissue-adhesive materials |
KR100822418B1 (ko) * | 2001-01-30 | 2008-04-16 | 엘티에스 로만 테라피-시스템 악티엔게젤샤프트 | 카복실기 함유 비스테로이드성 소염제 투여용 경피 치료 투여 제형, 및 그 제조 방법 |
WO2012010238A1 (en) | 2010-07-17 | 2012-01-26 | Merck Patent Gmbh | Enhancement of penetration and action |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7629384B2 (en) * | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
DE10003767A1 (de) * | 2000-01-28 | 2001-10-04 | Beiersdorf Ag | Hautfreundliches Wirkstoffpflaster zur transdermalen Verabreichung nichtsteroidaler Antirheumatika |
WO2001056475A1 (en) * | 2000-02-03 | 2001-08-09 | Tissuemed Limited | Device for the closure of a surgical puncture |
US6455067B1 (en) * | 2000-05-24 | 2002-09-24 | Sang-A Pharmaceutical Co., Ltd. | Transdermal patch for nonsteroidal antiinflammatory drug(s) |
DE10049225A1 (de) * | 2000-09-28 | 2002-04-11 | Labtec Gmbh | Dermales System, enthaltend Diclofenac |
AU2001295765B2 (en) * | 2000-10-23 | 2006-02-23 | Tissuemed Limited | Self-adhesive hydratable matrix for topical therapeutic use |
AU2004226578A1 (en) * | 2003-04-04 | 2004-10-14 | Tissuemed Limited | Tissue-adhesive formulations |
WO2005081964A2 (en) * | 2004-02-23 | 2005-09-09 | Strategic Science & Technologies, Llc | Topical delivery of a nitric oxide donor to improve body and skin appearance |
WO2005102307A2 (en) * | 2004-04-19 | 2005-11-03 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
DE102004039728A1 (de) * | 2004-08-16 | 2006-02-23 | Beiersdorf Ag | Wirkstoffhaltiges Tape zur Behandlung von Gelenkerkrankungen |
DE102004062182B4 (de) * | 2004-12-20 | 2007-06-06 | Bayer Schering Pharma Ag | Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff |
US20060134188A1 (en) * | 2004-12-20 | 2006-06-22 | Hans-Peter Podhaisky | Transdermal pharmaceutical preparation with a progesterone A-specific ligand (PRASL) as active ingredient |
KR100663163B1 (ko) * | 2005-10-24 | 2007-01-02 | (주)아모레퍼시픽 | 비스테로이드성 소염진통제를 함유하는 경피 투여 제제 |
JP2009525109A (ja) | 2006-02-03 | 2009-07-09 | ティシューメッド リミテッド | 組織接着材料 |
US8408781B2 (en) * | 2006-02-21 | 2013-04-02 | Charles D. Welker | System, method and apparatus for entraining air in concrete |
US20090018575A1 (en) * | 2006-03-01 | 2009-01-15 | Tissuemed Limited | Tissue-adhesive formulations |
GB0715514D0 (en) * | 2007-08-10 | 2007-09-19 | Tissuemed Ltd | Coated medical devices |
US20090291127A1 (en) * | 2008-05-21 | 2009-11-26 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
BRPI0917862A2 (pt) * | 2008-09-30 | 2015-11-24 | Teikoku Pharma Usa Inc | composições transdérmicas de donepezil com distribuição prolongada e métodos para usar as mesmas |
CN101721394B (zh) * | 2008-10-29 | 2013-04-17 | 大连理工大学 | 一种格拉司琼和/或其盐酸盐贴剂 |
CN101502499B (zh) * | 2009-03-13 | 2011-07-27 | 北京化工大学 | 一种布洛芬经皮释放贴剂及其制备方法 |
EP2445493A1 (de) | 2009-06-24 | 2012-05-02 | Strategic Science & Technologies, LLC | Topische zusammensetzung mit naproxen |
US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
BRPI0925099A2 (pt) | 2009-06-24 | 2018-10-16 | Strategic Science & Tech Llc | composição tópica contendo ibuprofeno |
US20100178307A1 (en) * | 2010-01-13 | 2010-07-15 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
CN103429247A (zh) | 2010-12-29 | 2013-12-04 | 战略科学与技术有限责任公司 | 勃起功能障碍和其它适应症的治疗 |
WO2012092523A1 (en) | 2010-12-29 | 2012-07-05 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
AU2013370290A1 (en) * | 2012-12-28 | 2015-07-16 | Noven Pharmaceuticals, Inc. | Compositions and methods for transdermal delivery of non-steroidal anti-inflammatory agents |
WO2014159798A1 (en) | 2013-03-13 | 2014-10-02 | Avery Dennison Corporation | Improving adhesive properties |
US10897978B2 (en) | 2014-10-21 | 2021-01-26 | The Procter & Gamble Company | Method of improving skin appearance |
WO2017070077A1 (en) | 2015-10-22 | 2017-04-27 | The Procter & Gamble Company | Barrier patch of a foamed film and methods of improving skin appearance |
US9872816B2 (en) | 2015-10-22 | 2018-01-23 | The Procter & Gamble Company | Barrier patch of a foamed film and methods of improving skin appearance |
US10576023B2 (en) | 2015-10-22 | 2020-03-03 | The Procter & Gamble Company | Barrier patch of a foamed film and methods of improving skin appearance |
CA3038702A1 (en) * | 2016-10-18 | 2018-04-26 | Lts Lohmann Therapie-Systeme Ag | Two-layer topical therapeutic system |
US10857076B2 (en) | 2017-01-09 | 2020-12-08 | The Procter & Gamble Company | Barrier patch with soluble film and methods of improving skin appearance |
EP3565642A1 (de) | 2017-01-09 | 2019-11-13 | The Procter and Gamble Company | Barrierepflaster mit löslicher folie und verfahren zur verbesserung des hautbildes |
US10751265B2 (en) | 2017-01-09 | 2020-08-25 | The Procter & Gamble | Barrier patch with soluble film and methods of improving skin appearance |
WO2018237214A1 (en) | 2017-06-22 | 2018-12-27 | The Procter & Gamble Company | BEAUTY MASK FILMS COMPRISING A WATER SOLUBLE LAYER AND A VACUUM EVAPORATED COATING |
WO2019183010A1 (en) | 2018-03-19 | 2019-09-26 | The Procter & Gamble Company | Method of making a barrier patch with soluble film |
KR101964264B1 (ko) * | 2018-09-04 | 2019-04-01 | 한국생산기술연구원 | 점착소재 및 이의 이용 |
KR102600712B1 (ko) * | 2021-09-27 | 2023-11-10 | 단국대학교 천안캠퍼스 산학협력단 | 체온감응형 고분자를 이용한 항류머티스제의 전달용 약제학적 조성물, 이를 포함하는 패치 및 이의 제조방법 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0319988A1 (de) * | 1987-12-09 | 1989-06-14 | Showa Denko Kabushiki Kaisha | Aüsserliche dermatologische Zubereitung |
JPH05238931A (ja) * | 1992-02-27 | 1993-09-17 | Nitto Denko Corp | 貼付剤 |
DE19706824C1 (de) * | 1997-02-21 | 1998-03-26 | Lohmann Therapie Syst Lts | Transdermales oder topisches Plastersystem mit Polyacrylatmatrix mit verbesserten physikalischen Eigenschaften |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0011471B1 (de) * | 1978-11-17 | 1983-02-09 | SMITH & NEPHEW RESEARCH LIMITED | Mit einem bakterientötende Mittel enthaltenden Klebstoff versehenes Folienmaterial |
JPS5843368B2 (ja) * | 1980-10-30 | 1983-09-27 | 日東電工株式会社 | 消炎鎮痛貼付剤 |
US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
FR2635979B1 (fr) * | 1988-09-07 | 1992-05-29 | Lhd Lab Hygiene Dietetique | Dispositif auto-adhesif d'administration d'un principe actif par voie percutanee |
WO1990006120A1 (en) * | 1988-12-01 | 1990-06-14 | Schering Corporation | Compositions for transdermal delivery of estradiol |
US5252334A (en) * | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
DE4020144A1 (de) * | 1990-06-25 | 1992-01-09 | Lohmann Therapie Syst Lts | Pflaster mit hohem gehalt an weichmachenden inhaltsstoffen |
JP2875611B2 (ja) * | 1990-08-29 | 1999-03-31 | エーザイ株式会社 | ケイ酸カルシウム含有外用剤 |
DE69228313T2 (de) * | 1991-08-30 | 1999-09-23 | Hisamitsu Pharmaceutical Co | Entzündungshemmendes, analgetisches pflaster |
IT1253265B (it) * | 1991-11-25 | 1995-07-14 | Rotta Research Lab | Preparato a matrice copolimerica adesiva a base acrilica per il rilascio transdermico dell'estradiolo. |
GB2273044B (en) | 1992-12-02 | 1997-04-09 | Pacific Chem Co Ltd | Medicinal patches for percutaneous administration |
DE4339400A1 (de) * | 1993-11-18 | 1995-05-24 | Hexal Pharma Gmbh | Wirkstoffpflaster |
ZA945718B (en) * | 1993-08-03 | 1995-03-09 | Osi Specialties Inc | Process for forming polyurethane foam using mechanical cooling and an additive |
FR2719770A1 (fr) * | 1994-05-11 | 1995-11-17 | Lhd Lab Hygiene Dietetique | Système matriciel pour administration transdermique d'ibuprofène et procédé de préparation. |
EP0781553B1 (de) * | 1994-09-16 | 2008-03-26 | Hisamitsu Pharmaceutical Co., Inc. | Pflaster zur externen anwendung |
US5702720A (en) * | 1995-12-22 | 1997-12-30 | Minnesota Mining And Manufacturing Company | Transdermal device for the delivery of flurbiprofen |
KR100228514B1 (ko) * | 1996-09-05 | 1999-11-01 | 한승수 | 비스테로이드성 소염진통제를 활성성분으로 하는 경피흡수제제의 제조방법 |
-
1998
- 1998-07-09 DE DE19830649A patent/DE19830649C2/de not_active Expired - Fee Related
-
1999
- 1999-07-06 US US09/743,124 patent/US6676962B1/en not_active Expired - Lifetime
- 1999-07-06 CZ CZ2001118A patent/CZ290992B6/cs unknown
- 1999-07-06 NZ NZ509216A patent/NZ509216A/en not_active IP Right Cessation
- 1999-07-06 AT AT99932827T patent/ATE251900T1/de active
- 1999-07-06 PL PL345535A patent/PL192009B1/pl unknown
- 1999-07-06 ES ES99932827T patent/ES2212584T3/es not_active Expired - Lifetime
- 1999-07-06 AU AU49075/99A patent/AU750861B2/en not_active Expired
- 1999-07-06 MX MXPA01000128A patent/MXPA01000128A/es active IP Right Grant
- 1999-07-06 DE DE59907381T patent/DE59907381D1/de not_active Expired - Lifetime
- 1999-07-06 CN CNB99808428XA patent/CN1222280C/zh not_active Expired - Lifetime
- 1999-07-06 WO PCT/EP1999/004686 patent/WO2000002539A1/de active IP Right Grant
- 1999-07-06 EP EP99932827A patent/EP1094796B1/de not_active Expired - Lifetime
- 1999-07-06 TR TR2001/00022T patent/TR200100022T2/xx unknown
- 1999-07-06 KR KR1020017000358A patent/KR100549847B1/ko not_active IP Right Cessation
- 1999-07-06 HU HU0103715A patent/HU227839B1/hu unknown
- 1999-07-06 JP JP2000558799A patent/JP2002520270A/ja active Pending
- 1999-07-06 RU RU2001102045/14A patent/RU2212232C2/ru active
- 1999-07-06 BR BRPI9911981-1A patent/BR9911981B1/pt not_active IP Right Cessation
- 1999-07-06 IL IL14074499A patent/IL140744A0/xx active IP Right Grant
- 1999-07-06 CA CA002336732A patent/CA2336732C/en not_active Expired - Lifetime
- 1999-07-07 AR ARP990103302A patent/AR019343A1/es active IP Right Grant
- 1999-07-09 TW TW088111648A patent/TW577760B/zh not_active IP Right Cessation
-
2000
- 2000-01-04 IL IL140744A patent/IL140744A/en not_active IP Right Cessation
-
2001
- 2001-01-08 ZA ZA200100172A patent/ZA200100172B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0319988A1 (de) * | 1987-12-09 | 1989-06-14 | Showa Denko Kabushiki Kaisha | Aüsserliche dermatologische Zubereitung |
JPH05238931A (ja) * | 1992-02-27 | 1993-09-17 | Nitto Denko Corp | 貼付剤 |
DE19706824C1 (de) * | 1997-02-21 | 1998-03-26 | Lohmann Therapie Syst Lts | Transdermales oder topisches Plastersystem mit Polyacrylatmatrix mit verbesserten physikalischen Eigenschaften |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Derwent World Patents Index; AN 1993-331354, XP002117847 * |
PATENT ABSTRACTS OF JAPAN vol. 017, no. 704 (C - 1146) 22 December 1993 (1993-12-22) * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10032537A1 (de) * | 2000-07-05 | 2002-01-31 | Labtec Gmbh | Dermales System, enthaltend 2-(3-Benzophenyl)Propionsäure |
KR100822418B1 (ko) * | 2001-01-30 | 2008-04-16 | 엘티에스 로만 테라피-시스템 악티엔게젤샤프트 | 카복실기 함유 비스테로이드성 소염제 투여용 경피 치료 투여 제형, 및 그 제조 방법 |
AU2002367083B2 (en) * | 2001-12-21 | 2008-02-28 | Coloplast A/S | A wound care device |
EP1576969A1 (de) * | 2001-12-21 | 2005-09-21 | Coloplast A/S | Artikel zur Wundbehandlung |
WO2003055536A1 (en) * | 2001-12-21 | 2003-07-10 | Coloplast A/S | A wound care device |
US8790688B2 (en) | 2001-12-21 | 2014-07-29 | Coloplast A/S | Wound care device for local treatment of pain in a wound |
WO2004110511A1 (en) * | 2003-06-19 | 2004-12-23 | Coloplast A/S | A wound care device |
AU2004246757B2 (en) * | 2003-06-19 | 2009-01-08 | Coloplast A/S | A wound care device |
EP2279763A1 (de) * | 2003-06-19 | 2011-02-02 | Coloplast A/S | Artikel zur Wundbehandlung |
US8409610B2 (en) | 2003-06-19 | 2013-04-02 | Coloplast A/S | Wound care device |
WO2006013337A2 (en) | 2004-08-03 | 2006-02-09 | Tissuemed Limited | Tissue-adhesive materials |
WO2006013337A3 (en) * | 2004-08-03 | 2006-09-14 | Tissuemed Ltd | Tissue-adhesive materials |
WO2012010238A1 (en) | 2010-07-17 | 2012-01-26 | Merck Patent Gmbh | Enhancement of penetration and action |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1094796B1 (de) | Topisches pflaster mit nichtsteroidalen antirheumatika mit säuregruppe | |
EP0464573B1 (de) | Pflaster mit hohem Gehalt an weichmachenden Inhaltsstoffen | |
DE4241874C2 (de) | Medizinisches Pflaster für die perkutane Verabreichung des Wirkstoffs Ketoprofen | |
EP0848950B1 (de) | Haft- und Bindemittel aus (Meth)acrylatpolymer, organischer Säure und Weichmacher | |
EP1009393B1 (de) | Transdermales therapeutisches system mit haftklebender reservoirschicht und unidirektional elastischer rückschicht | |
DE10026678C1 (de) | Transdermales Pflaster für einen entzündungshemmenden Wirkstoff oder für entzündungshemmende Wirkstoffe | |
EP0720474B1 (de) | Lösemittelfrei herstellbares wirkstoffpflaster enthaltend flüchtige inhaltsstoffe | |
EP1171104A2 (de) | Transdermales therapeutisches system mit neutralisierten acrylhaftklebern | |
DE602004010248T2 (de) | Externes pflaster mit östrogen und/oder gestagen | |
WO1994016707A1 (de) | Transdermales therapeutisches system mit galanthamin als wirksamen bestandteil | |
DE10212864B4 (de) | Polymermatrizes umfassend ein Mischsystem zur Löslichkeitsvermittlung von pharmazeutischen Wirkstoffen, Verfahren zu deren Herstellung und deren Verwendung | |
EP1355636B1 (de) | Transdermales therapeutisches system für die verabreichung carboxylgruppenhaltiger, nichtsteroidaler antiphlogistika, sowie verfahren zu seiner herstellung | |
EP1450773B1 (de) | Transdermales therapeutisches system mit verbessertem langzeittragekomfort | |
DE60126607T2 (de) | Element zur applikation einer salbe und ein salbenpflaster, das dieses verwendet | |
EP0781134B9 (de) | Scopolaminpflaster | |
DE10110391A1 (de) | Hochflexibles Nikotin transdermales therapeutisches System mit Nikotin als Wirkstoff | |
EP1143938B1 (de) | Transdermales therapeutisches system mit einer selbstklebenden matrix, enthaltend organische säure-additionssalze von alkaloiden des morphin- bzw. morphinantyps | |
EP1220661B1 (de) | Transdermales therapeutisches system zur abgabe von acetylsalicylsäure und/oder salicylsäure | |
EP1284718B1 (de) | Okklusives transdermales therapeutisches system mit nicht-okklusiver rückschicht | |
DE10035891A1 (de) | Medizinischer Haftkleber mit einer zweiphasigen Klebermatrix aus Polyacrylaten und Polyaminsalzen | |
WO2006018340A9 (de) | Wirkstoffhaltiges tape zur behandlung von gelenkerkrankungen | |
DE4438989C2 (de) | Scopolaminpflaster | |
DE102017115701B4 (de) | Fampridin-TTS | |
DE10025971A1 (de) | Transdermales therapeutisches System mit verminderter Tendenz zur Wirkstoffkristallisation | |
DE19840191A1 (de) | Arzneistoffhaltiges Pflaster mit drei funktionalen Schichten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99808428.X Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN CZ HU IL IN JP KR MX NZ PL RU TR US ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999932827 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 509216 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2336732 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001/00172 Country of ref document: ZA Ref document number: PA/a/2001/000128 Country of ref document: MX Ref document number: 200100172 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref document number: 2000 558799 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017000358 Country of ref document: KR Ref document number: PV2001-118 Country of ref document: CZ Ref document number: 2001/00022 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 49075/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/00087/DE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2001/00113/DE Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09743124 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999932827 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-118 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017000358 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: PV2001-118 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 49075/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999932827 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020017000358 Country of ref document: KR |